[
  {
    "ts": "2025-11-08T02:31:00+00:00",
    "headline": "Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash.",
    "url": "https://finance.yahoo.com/news/pfizer-metsera-enter-merger-agreement-023100002.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "28cc0f00-9e6d-3c8e-9327-91db16df85f0",
      "content": {
        "id": "28cc0f00-9e6d-3c8e-9327-91db16df85f0",
        "contentType": "STORY",
        "title": "Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer",
        "description": "",
        "summary": "Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash.",
        "pubDate": "2025-11-08T02:31:00Z",
        "displayTime": "2025-11-08T02:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/eb406e6c71b993a03bb9115a8790db25",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h6khLfW7xyx4j3pmDWGaBQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/eb406e6c71b993a03bb9115a8790db25.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IJ6HuEqvDy1cyfEeho5IfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb406e6c71b993a03bb9115a8790db25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-metsera-enter-merger-agreement-023100002.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-metsera-enter-merger-agreement-023100002.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T03:50:00+00:00",
    "headline": "Pfizer and Metsera Reach Deal Expected to Top $10 Billion",
    "summary": "Pfizer  has agreed to buy the weight-loss drug startup  Metsera  in a deal that could be worth more than $10 billion, besting  Novo Nordisk  following a heated bidding war.  Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday.  In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.",
    "url": "https://www.wsj.com/health/pharma/pfizer-and-metsera-reach-deal-worth-up-to-10-billion-be5def52?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "fef399b8-e95d-3d7b-a294-f60dd4869bb5",
      "content": {
        "id": "fef399b8-e95d-3d7b-a294-f60dd4869bb5",
        "contentType": "STORY",
        "title": "Pfizer and Metsera Reach Deal Expected to Top $10 Billion",
        "description": "",
        "summary": "Pfizer  has agreed to buy the weight-loss drug startup  Metsera  in a deal that could be worth more than $10 billion, besting  Novo Nordisk  following a heated bidding war.  Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday.  In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.",
        "pubDate": "2025-11-08T03:50:00Z",
        "displayTime": "2025-11-08T03:50:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/fef399b8-e95d-3d7b-a294-f60dd4869bb5/pfizer-and-metsera-reach-deal.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/3b6774ea810b8f54759159222b795648",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yHjLxewpFGrzQE7iCtUZFQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/3b6774ea810b8f54759159222b795648.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bJVENmQP35_X8rYjPcVNrg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/3b6774ea810b8f54759159222b795648.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/pfizer-and-metsera-reach-deal-worth-up-to-10-billion-be5def52?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T10:12:58+00:00",
    "headline": "Metsera (MTSR) Hits New High on Billion-Dollar Bidding War",
    "summary": "We recently published 10 Stocks on Fire Amid Market Chaos. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera soared to a new all-time high on Thursday as buying appetite was bolstered by an intensifying billion-dollar bidding war from two pharmaceutical giants. At intra-day trading, Metsera, Inc. (NASDAQ:MTSR) climbed to a new […]",
    "url": "https://finance.yahoo.com/news/metsera-mtsr-hits-high-billion-101258734.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4c62dc6e-e873-31bc-acea-a8ee137ab27c",
      "content": {
        "id": "4c62dc6e-e873-31bc-acea-a8ee137ab27c",
        "contentType": "STORY",
        "title": "Metsera (MTSR) Hits New High on Billion-Dollar Bidding War",
        "description": "",
        "summary": "We recently published 10 Stocks on Fire Amid Market Chaos. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera soared to a new all-time high on Thursday as buying appetite was bolstered by an intensifying billion-dollar bidding war from two pharmaceutical giants. At intra-day trading, Metsera, Inc. (NASDAQ:MTSR) climbed to a new […]",
        "pubDate": "2025-11-08T10:12:58Z",
        "displayTime": "2025-11-08T10:12:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b05bd7844473a889646b0e4df5e28942",
          "originalWidth": 1000,
          "originalHeight": 695,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u.5dqvTgkxbQEhP4DAHtvA--~B/aD02OTU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b05bd7844473a889646b0e4df5e28942.cf.webp",
              "width": 1000,
              "height": 695,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/no_bFNGO36z1IOi6BC93jA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b05bd7844473a889646b0e4df5e28942.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/metsera-mtsr-hits-high-billion-101258734.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/metsera-mtsr-hits-high-billion-101258734.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T09:17:52+00:00",
    "headline": "Pfizer wins $10 billion bidding war for weight-loss start-up Metsera",
    "summary": "Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo...",
    "url": "https://finance.yahoo.com/news/pfizer-wins-10bn-bidding-war-091752111.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "f2e79691-4999-3e07-8067-b43133db97a2",
      "content": {
        "id": "f2e79691-4999-3e07-8067-b43133db97a2",
        "contentType": "STORY",
        "title": "Pfizer wins $10 billion bidding war for weight-loss start-up Metsera",
        "description": "",
        "summary": "Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo...",
        "pubDate": "2025-11-08T09:17:52Z",
        "displayTime": "2025-11-08T13:02:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/9e822ae0-bca2-11f0-8fef-73cba373afd6",
          "originalWidth": 5263,
          "originalHeight": 3509,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G7BPmHsNeiHwnr_nNpRCAw--~B/aD0zNTA5O3c9NTI2MzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/9e822ae0-bca2-11f0-8fef-73cba373afd6.cf.webp",
              "width": 5263,
              "height": 3509,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LRlnByDHh5AsH7p7O937dg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/9e822ae0-bca2-11f0-8fef-73cba373afd6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-wins-10bn-bidding-war-091752111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-wins-10bn-bidding-war-091752111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T13:17:54+00:00",
    "headline": "Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits",
    "summary": "<body><p>STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.</p><p>It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race.&nbsp;</p><p>Metsera accepted a sweetened offer from Pfizer late Friday (November 7).&nbsp;</p><p>It cited U.S. antitrust risks in Novo's bid that it had previously called superior.&nbsp;</p><p>Novo said in a statement that it believed its offer structure was \"compliant with antitrust laws.\"</p><p>Metsera’s drugs are projected to reach $5 billion in peak sales.</p><p>And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves.&nbsp;</p><p>It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.</p><p>The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…</p><p>And that it would \"continue to assess opportunities for business development and acquisitions”.</p><p>Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.</p></body>",
    "url": "https://finance.yahoo.com/video/pfizer-wins-10-billion-metsera-131754240.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "2c36a3b2-80db-36ec-9635-1d51c7a756f3",
      "content": {
        "id": "2c36a3b2-80db-36ec-9635-1d51c7a756f3",
        "contentType": "VIDEO",
        "title": "Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits",
        "description": "<title><body><p>STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.</p><p>It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. </p><p>Metsera accepted a sweetened offer from Pfizer late Friday (November 7). </p><p>It cited U.S. antitrust risks in Novo's bid that it had previously called superior. </p><p>Novo said in a statement that it believed its offer structure was \"compliant with antitrust laws.\"</p><p>Metsera’s drugs are projected to reach $5 billion in peak sales.</p><p>And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. </p><p>It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.</p><p>The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…</p><p>And that it would \"continue to assess opportunities for business development and acquisitions”.</p><p>Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.</p></body></title>",
        "summary": "<body><p>STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.</p><p>It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race.&nbsp;</p><p>Metsera accepted a sweetened offer from Pfizer late Friday (November 7).&nbsp;</p><p>It cited U.S. antitrust risks in Novo's bid that it had previously called superior.&nbsp;</p><p>Novo said in a statement that it believed its offer structure was \"compliant with antitrust laws.\"</p><p>Metsera’s drugs are projected to reach $5 billion in peak sales.</p><p>And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves.&nbsp;</p><p>It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.</p><p>The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…</p><p>And that it would \"continue to assess opportunities for business development and acquisitions”.</p><p>Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.</p></body>",
        "pubDate": "2025-11-08T13:17:54Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/HNAqrGnt5gVBy0xfSVuwPg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/69283cf3-c987-4e22-aa84-769c1c3e5920/main/1280x720/32s612ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Yc2aWJhW2_VwVLCajqlEBw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/69283cf3-c987-4e22-aa84-769c1c3e5920/main/1280x720/32s612ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b9sF7Tdujq63CMyRIHRU9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/69283cf3-c987-4e22-aa84-769c1c3e5920/main/1280x720/32s612ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/pfizer-wins-10-billion-metsera-131754240.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/pfizer-wins-10-billion-metsera-131754240.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T14:15:00+00:00",
    "headline": "2 No-Brainer Dividend Stocks to Buy With $100 in November",
    "summary": "There's no need to break the bank to get your hands on excellent dividend payers.",
    "url": "https://www.fool.com/investing/2025/11/08/2-no-brainer-dividend-stocks-to-buy-in-november/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "039d3f09-cdc5-36a9-b38c-edb9859be8b9",
      "content": {
        "id": "039d3f09-cdc5-36a9-b38c-edb9859be8b9",
        "contentType": "STORY",
        "title": "2 No-Brainer Dividend Stocks to Buy With $100 in November",
        "description": "",
        "summary": "There's no need to break the bank to get your hands on excellent dividend payers.",
        "pubDate": "2025-11-08T14:15:00Z",
        "displayTime": "2025-11-08T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/358ca2d5bf7215344cd756cc18502e7e",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Couple shopping in retail store.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QZvCoTvkUqeqLpXSTQL8Iw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/358ca2d5bf7215344cd756cc18502e7e.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QpxtVCiyhPRp7SKkuFXHJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/358ca2d5bf7215344cd756cc18502e7e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/08/2-no-brainer-dividend-stocks-to-buy-in-november/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-no-brainer-dividend-stocks-141500368.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T13:52:00+00:00",
    "headline": "This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed.",
    "summary": "The founders of Metsera had a battle to buy their company. It’s their second time striking deal gold.",
    "url": "https://www.wsj.com/health/pharma/metsera-pfizer-bid-weight-loss-drugs-e95dadcc?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "04f80ce8-0931-3b97-9f3c-4de6cb72d189",
      "content": {
        "id": "04f80ce8-0931-3b97-9f3c-4de6cb72d189",
        "contentType": "STORY",
        "title": "This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed.",
        "description": "",
        "summary": "The founders of Metsera had a battle to buy their company. It’s their second time striking deal gold.",
        "pubDate": "2025-11-08T13:52:00Z",
        "displayTime": "2025-11-08T13:52:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/04f80ce8-0931-3b97-9f3c-4de6cb72d189/this-unlikely-duo-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6733447ed0f1fbe1f832faffd6c0e15d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iMbL84xpcQXGNaDasIdrsA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6733447ed0f1fbe1f832faffd6c0e15d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DKP9j8iYwslqMrh5vgFjtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6733447ed0f1fbe1f832faffd6c0e15d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/metsera-pfizer-bid-weight-loss-drugs-e95dadcc?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVN.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]